Funding

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Alexandre DIAS (IMATHERA, CGFL) obtained funding through the young researcher programm of ANR of €324,000 over 3 years (2024-2027). This project entitled “Improved imaging and therapy of HER2-low breast cancer” (EITHER2BC) aims at developing theranostic probes (combining properties for diagnosis and therapy) targeting HER2, in a HER2-low context, could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of these patients. This project will be driven in collaboration with ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the INCA of €130,000 over 3 years (2024-2027) as partner of a global INCA project entitled “Development of bimodal antibodies targeting colorectal and pancreatic tumors for fluorescenceguided surgery application”. This project is led by Dr Catherine Paul (École Pratique des Hautes Études – Université PSL) and in collaboration with the ICMUB (Dr Goze Christine) and Besançon University Hospital (Dr Doussot Alexandre).

​

Probes developed in this prject will be tested for FGS in various preclinical models mimicking human pathology, such as orthotopic models of colon and pancreatic cancers, but also models mimicking the formation of liver metastases or peritoneal carcinomatosis. The expected results of this project are fine visualisation of tumours before surgery (SPECT imaging) and more accurate detection by fluorescence, enabling the extent of resection to be minimised. Finally, it will be possible to detect the absence of recurrence using this compound a few weeks after surgery (SPECT).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Drs Alexandre COCHET and Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the FEDER of 3.6 M€ over 5 years (2023-2028). This project entitled “moleCular radiOtherapy for Metastatic ColorEcTal and Gastric cancErs” (COMETE) aims at developing theranostic probes (for RIT and associated companion diagnostics) in colorectal and gastric cancers that could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of patients.

This project will be driven by Oncodesign Precision Medicine (OPM, Dijon) with a third parter, ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).